Question 1

How many shares of MLTX does CITADEL ADVISORS LLC own?

Accepted Answer

As of 2026-Q2, CITADEL ADVISORS LLC holds 2M shares of MLTX (MoonLake Immunotherapeutics Class A).

Question 2

What is CITADEL ADVISORS LLC's MLTX position worth?

Accepted Answer

As of 2026-Q2, CITADEL ADVISORS LLC's MLTX position is worth $38.4M.

Question 3

Is CITADEL ADVISORS LLC buying or selling MLTX?

Accepted Answer

In 2026-Q2, CITADEL ADVISORS LLC increased their MLTX position (+49.0% change in shares).

Question 4

When did CITADEL ADVISORS LLC first buy MLTX?

Accepted Answer

Based on available 13F filings, CITADEL ADVISORS LLC first reported a position in MLTX in 2024-Q3. They have held the position across 17 quarters.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Increased	2M	+49.0%	$38.4M	0.0%	$19.47	40
2026-Q1	Increased	1.3M	+247.5%	$24.7M	0.0%	$17.69	46
2025-Q4	Increased	380,890	+672.1%	$5M	0.0%	$13.21	43
2025-Q3	Decreased	49,334	-97.0%	$353,725	0.0%	$6.24	0
2025-Q2	Increased	1.7M	+13.2%	$79M	0.0%	$47.52	34
2025-Q1	Decreased	1.5M	-32.4%	$57.8M	0.0%	$39.86	0
2024-Q4	Decreased	2.2M	-5.9%	$118.4M	0.0%	$53.02	0
2024-Q3	Increased	2.3M	+2.5%	$117.1M	0.0%	$49.40	31